CRISPR Therapeutics
CRSP
436 hedge funds and large institutions have $3.52B invested in CRISPR Therapeutics in 2025 Q2 according to their latest regulatory filings, with 100 funds opening new positions, 129 increasing their positions, 101 reducing their positions, and 60 closing their positions.
117% more capital inflows, than outflows
Capital inflows: $569M | Capital outflows: $262M
67% more first-time investments, than exits
New positions opened: 100 | Existing positions closed: 60
31% more call options, than puts
Call options by funds: $244M | Put options by funds: $186M
28% more repeat investments, than reductions
Existing positions increased: 129 | Existing positions reduced: 101
9% more funds holding
Funds holding: 400 → 436 (+36)
8.39% more ownership
Funds ownership: 75.4% → 83.79% (+8.4%)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$134M |
| 2 |
Orbis Allan Gray
Hamilton,
Bermuda
|
+$46.5M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$39.7M |
| 4 |
State Street
Boston,
Massachusetts
|
+$33.3M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$29.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS AM
Chicago,
Illinois
|
-$38.2M |
| 2 |
Morgan Stanley
New York
|
-$30.5M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
-$22.3M |
| 4 |
Millennium Management
New York
|
-$19.9M |
| 5 |
Capital International Investors
Los Angeles,
California
|
-$18.6M |
CRSP Hedge Fund Activity: Q2 2025 in Review
436 of the 7,634 institutional investors tracked by Wall St. Rank reported a position in CRISPR Therapeutics (CRSP) for Q2 2025, worth a combined $3.52B — up 60% from $2.2B a quarter earlier.
Buyers outnumbered sellers: 100 funds opened new CRSP positions and 60 closed out — a net gain of 40 holders — while 129 added to existing stakes and 101 trimmed.
The largest buyer was BlackRock, adding an estimated $134M. The largest seller was UBS AM, cutting an estimated $38.2M.
- 436 institutional investors held CRISPR Therapeutics (CRSP) as of Q2 2025, up from 400 in Q1 2025.
- Funds reported $3.52B of CRISPR Therapeutics stock for Q2 2025, up 60% quarter-over-quarter.
- 100 funds opened new CRISPR Therapeutics positions in Q2 2025 and 60 closed out, a net change of +40 holders.
- The largest CRISPR Therapeutics buyer in Q2 2025 was BlackRock, an estimated $134M added.
- The largest CRISPR Therapeutics seller in Q2 2025 was UBS AM, an estimated $38.2M sold.
Based on aggregated 13F filings for Q2 2025.